ACE, ARB May Benefit Aortic Regurgitation

    Press/Media: Research


    Angiotensin-renin blockade in moderate-to-severe aortic regurgitation may reduce heart failure and mortality risks, a large population-based study suggested.

    The odds of dying from any cause were a significant 44% lower during 4.4 years of follow-up for those who received an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) among the more than 2,200 such patients studied by Chim C. Lang, of the University of Dundee, Scotland, and colleagues.

    The risk of heart failure hospitalizations, heart failure deaths, or aortic valve replacement was 32% lower with an ACE or ARB drug (P<0.01), the group reported in the Nov. 8 issue of the Journal of the American College of Cardiology. 

    Period31 Oct 2011

    Media coverage


    Media coverage

    • TitleACE, ARB May Benefit Aortic Regurgitation
      PersonsChim Lang